Legal Representation
Attorney
Dana B. Robinson
USPTO Deadlines
Application History
37 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Apr 10, 2017 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | Loading... |
| Apr 10, 2017 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Sep 24, 2016 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Sep 24, 2016 | NOAC | E | CORRECTED NOA E-MAILED | Loading... |
| Sep 23, 2016 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Sep 8, 2016 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Sep 23, 2016 | DPCC | D | DIVISIONAL PROCESSING COMPLETE | Loading... |
| Sep 8, 2016 | DRRR | I | DIVISIONAL REQUEST RECEIVED | Loading... |
| Sep 8, 2016 | ERTD | I | TEAS REQUEST TO DIVIDE RECEIVED | Loading... |
| Sep 8, 2016 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Aug 27, 2016 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Aug 27, 2016 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Jun 3, 2016 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jun 2, 2016 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Mar 8, 2016 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| May 27, 2016 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Apr 19, 2016 | NREV | E | NOTICE OF REVIVAL - E-MAILED | Loading... |
| Apr 19, 2016 | TPEX | I | SOU EXTENSION RECEIVED WITH TEAS PETITION | Loading... |
| Apr 19, 2016 | PETG | O | PETITION TO REVIVE-GRANTED | Loading... |
| Apr 19, 2016 | PROA | I | TEAS PETITION TO REVIVE RECEIVED | Loading... |
| Apr 11, 2016 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | Loading... |
| Apr 11, 2016 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Sep 8, 2015 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Jul 14, 2015 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Jul 14, 2015 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jun 24, 2015 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jun 10, 2015 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED | Loading... |
| Jun 10, 2015 | ALIE | A | ASSIGNED TO LIE | Loading... |
| May 20, 2015 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| May 20, 2015 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| May 20, 2015 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| May 20, 2015 | GNEA | F | EXAMINERS AMENDMENT E-MAILED | Loading... |
| May 20, 2015 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| May 11, 2015 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Feb 14, 2015 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Feb 13, 2015 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Feb 7, 2015 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical agents affecting metabolism; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the prevention of as well as management, diagnosis and prognosis of autoimmune, inflammatory, metastatic, hematologic, oncologic, neurologic and metabolic diseases, conditions, and disorders, and diseases, conditions, and disorders associated with misfolded proteins, and diseases, conditions and disorders affecting the systemic and central nervous system.; Pharmaceutical preparations for the treatment and prevention of as well as management, diagnosis and prognosis of the following specific list of enumerated indications: autoimmune, inflammatory, metastatic, hematologic, oncologic and neurologic diseases, conditions and disorders, and diseases, conditions and disorders associated with misfolded proteins, and diseases, conditions and disorders affecting the central nervous system, and psoriasis, psoriatic arthritis, rheumatoid arthritis, dermatitis, host/graft rejections, Alzheimer's and Parkinson's-disease, insulin resistance, systemic metabolic disorders, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, dementia pugilistica /chronic traumatic encephalopathy, inclusion body myositosis, mild cognitive impairment, chronic inflammation, Familial Mediterranean Fever, plasma cell (B-cell) dyscrasias, prion diseases, dialysis related amyloidosis and carpal tunnel syndrome, senile cardiac amyloidosis, Familial Amyloidotic Polyneuropathy, medullary carcinoma of the thyroid and type II diabetes
First Use Anywhere:
0
First Use in Commerce:
0
Additional Information
Design Mark
The mark consists of a counter clockwise spiraling group of shaded and variously sized and colored dots ranging from blue in the center dot and getting progressively lighter as the dots go farther from the center, ending with several green dots.
Color Claim
The color(s) green and blue is/are claimed as a feature of the mark.
Classification
International Classes
005